Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

PDUFA date for diabetes candidate albiglutide extended 3 months

Aug. 6, 2013

Aegerion obtains European approval for Lojuxta in HoFH

Aug. 5, 2013

Takeda receives marketing authorization in China for Nesina

Aug. 2, 2013

Baltic Bio synthesizes new AMPK activators for diabetes

Aug. 2, 2013

Catabasis reports encouraging results from phase I trial of CAT-2003

Aug. 1, 2013

Takeda Pharmaceuticals divulges novel MCH1 receptor antagonists

July 30, 2013

EMA committee recommends approval of three Takeda type 2 diabetes therapies

July 29, 2013

New GPR119 receptor agonists patented by Hyundai Pharmaceutical

July 29, 2013

Jiangsu Hengrui Medicine synthesizes novel GPR40 agonists

July 26, 2013

AstraZeneca and Bristol-Myers Squibb resubmit NDA for dapagliflozin

July 26, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...